Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells
Open Access
- 27 April 2025
- journal article
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (5)
Abstract
Low dose methotrexate (LD‐MTX) remains the gold standard in rheumatoid arthritis (RA) therapy. Multiple mechanisms on a variety of immune cells contribute to the anti‐inflammatory effects of LD‐MTX. Inflammatory signaling is deeply implicated in hematopoiesis by regulating hematopoietic stem and progenitor cell (HSPC) fate decisions; raising the question of whether HSPC are also modulated by LD‐MTX. This is the first study to characterize the effects of LD‐MTX on HSPC. CD34+ HSPC were isolated from healthy donors' non‐mobilized peripheral blood. Resting and/or cycling HSPCs were treated with LD‐MTX [dose equivalent to that used in RA patients]. Flow cytometry was performed to assess HSPC viability, cell cycle, surface abundance of reduced folate carrier 1 (RFC1), proliferation, reactive oxygen species (ROS) levels, DNA double‐strand breaks, p38 activation, and CD34+ subpopulations. HSPC clonogenicity was tested in colony‐forming cell assays. Our results indicate that in cycling HSPC, membrane RFC1 is upregulated and, following LD‐MTX treatment, they accumulate more intracellular MTX than resting HSPC. In cycling HSPC, LD‐MTX inhibits HSPC expansion by promoting S‐phase cell‐cycle arrest, increases intracellular HSPC ROS levels and DNA damage, and reduces HSPC viability. Those effects involve the activation of the p38 MAPK pathway and are rescued by folinic acid. The effects of LD‐MTX are more evident in CD34+ CD38High progenitors. In non‐cycling HSPC, LD‐MTX also reduces the proliferative response while preserving their clonogenicity. In summary, HSPC uptake LD‐MTX differentially according to their cycling state. In turn, LD‐MTX results in reduced proliferation and the preservation of HSPC clonogenicity.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritisArthritis & Rheumatism, 2008
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- The anti‐inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen speciesBritish Journal of Pharmacology, 2003
- Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells.1999
- Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progenitor populationBlood, 1996
- Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium.Proceedings of the National Academy of Sciences, 1996
- Pancytopenia secondary to methotrexate therapy in rheumatoid arthritisArthritis & Rheumatism, 1996
- TOTAL AND FREE METHOTREXATE PHARMACOKINETICS, WITH AND WITHOUT PIROXICAM, IN RHEUMATOID ARTHRITIS PATIENTSRheumatology, 1995
- Cell cycle and functional differences between CD34+/CD38hi and CD34+/38lo human marrow cells after in vitro cytokine exposureBlood, 1995
- Efficacy of Low-Dose Methotrexate in Rheumatoid ArthritisNew England Journal of Medicine, 1985